FindTrial
Sign In

Understanding Long-Term Survivors of Solid Tumour: A Study to Learn and Help Others

Analysing and solving exceptional long-term survival in patients with poor prognosis solid tumors. - ROSALIND STUDY

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/08/093016
Enrollment
1659
Registered
2025-08-13
Start date
Unknown
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C719- Malignant neoplasm of brain, unspecified Health Condition 2: K868- Other specified diseases of pancreas

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: NA Control Intervention1: Nil: NA

Sponsors

Cure51
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with exceptional long-term survival cohort (case group) inclusion criteria: 1. Adult patient (More than 18 years old at diagnosis). 2. Three distinct cohorts: Cohort A: Metastatic pancreatic ductal adenocarcinoma (PDAC) (Other histologies such as adenosquamous carcinoma, hepatoid carcinoma, anaplastic undifferentiated carcinoma and medullary carcinoma, acinar cell carcinoma, neuroendocrine tumors, Solid pseudopapillary neoplasm, Pancreatoblastoma, Serous cystadenocarcinoma are excluded) Cohort B: Glioblastoma (GBM) (IDH mutated excluded) Cohort C: Extensive small cell lung cancer (SCLC) (Other histologies excluded: combined SCLC with some areas of non-small cell lung cancer (NSCLC), carcinoid tumors, typical and atypical, large cell neuroendocrine carcinoma of the lung).

Exclusion criteria

Exclusion criteria: 1. Less than 18 years old at diagnosis. 2. Hematological malignancy or solid tumors, which are not in the scope of tumor types, described in the inclusion criteria. 3. Tumor sample not available or not reaching the required quality for multiomic analyses

Design outcomes

Primary

MeasureTime frame
The primary endpoint is the case (long survivor)/control (standard survivor) status.Timepoint: Survival more than five years from diagnosis for Case.—

Secondary

MeasureTime frame
Identification of clinical, radiological, histopathological, and multi-omic (genomic, transcriptomic, proteomic, epigenomic) signatures associated with long-term survival - In each individual cancer cohort - Across all cohorts (pan-cohort)Timepoint: NA—

Countries

France, Germany, India

Contacts

Public ContactDr Vikas Ostwal

Tata Memorial Centre

dr.vikas.ostwal@gmail.com9702288801

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026